introduct
determin
caus
communityacquir
pneumonia
cap
remain
problemat
observ
studi
systemat
appli
current
approv
diagnost
techniqu
patient
hospit
cap
order
determin
proport
etiolog
agent
could
identifi
method
patient
admit
find
consist
cap
includ
sputum
blood
cultur
urin
test
pneumococc
legionella
antigen
nasopharyng
swab
viral
pcr
serum
procalcitonin
obtain
nearli
everi
case
admissionrel
electron
medic
record
review
entireti
result
final
clinic
diagnosi
patient
uninfect
caus
bacterium
identifi
case
pcr
identifi
respiratori
viru
document
bacteri
coinfect
caus
cap
found
syndrom
indistinguish
bacteri
pneumonia
procalcitonin
elev
patient
bacteri
infect
low
uninfect
patient
viral
infect
substanti
overlap
conclus
patient
admit
cap
syndrom
document
bacteri
infect
anoth
identifi
bacteri
etiolog
find
close
resembl
bacteri
infect
nevertheless
receiv
antibacteri
therapi
journal
infect
care
attent
clinic
pictur
may
identifi
uninfect
patient
viral
infect
perhap
reassur
nonelev
procalcitonin
determin
etiolog
diagnosi
remain
elus
better
discrimin
bacteri
infect
sore
need
publish
elsevi
ltd
behalf
british
infect
associ
etiolog
agent
identifi
adult
hospit
communityacquir
pneumonia
result
oneyear
studi
introduct
communityacquir
pneumonia
cap
remain
major
caus
morbid
mortal
adult
late
chang
host
diseas
pattern
develop
new
antibiot
great
divers
approach
treatment
led
creation
guidelin
initi
often
empir
treatment
cap
subsequ
demonstr
delay
therapi
contribut
poor
outcom
increas
tendenc
treat
empir
recent
guidelin
recommend
antibiot
administ
empir
point
care
diagnosi
cap
first
made
emphasi
immedi
treatment
pneumonia
certain
disadvantag
reduc
impetu
determin
caus
organ
unfortun
develop
time
contribut
streptococcu
pneumonia
may
decreas
rang
identifi
potenti
pathogen
greatli
expand
empir
therapi
also
led
use
antibiot
patient
infect
associ
increas
microbi
resist
undertook
prospect
observ
studi
patient
admit
medic
center
syndrom
consist
cap
hypothesi
care
collect
clinic
tradit
diagnost
microbiolog
data
togeth
use
newer
fdaapprov
techniqu
might
yield
suffici
inform
inform
decisionmak
admiss
find
show
etiolog
diagnosi
cap
far
elus
hypothes
everi
patient
hospit
syndrom
consist
diagnosi
cap
michael
e
debakey
veteran
affair
medic
center
medvamc
juli
june
ask
particip
nearli
patient
agre
sign
consent
form
approv
institut
review
board
baylor
colleg
medicin
cap
syndrom
defin
newli
recogn
pulmonari
infiltr
togeth
follow
find
subject
fever
document
temperatur
f
increas
cough
sputum
product
short
breath
pleurit
chest
pain
confus
rale
leukocytosi
white
blood
count
wbc
suppress
wbc
count
patient
cap
one
admit
diagnos
fact
receiv
antibiot
therapi
emerg
depart
although
requir
inclus
studi
patient
hospit
preced
week
bedbound
longterm
care
facil
known
aspir
exclud
record
patient
demograph
comorbid
condit
sick
contact
symptom
pulmonari
diseas
vital
sign
oxygen
satur
relev
physic
find
wbc
count
differenti
bnatriuret
protein
radiograph
find
blood
cultur
result
result
sputum
gram
stain
cultur
specif
note
adequaci
sputum
sampl
time
antibiot
administr
time
sputum
collect
nasopharyng
swab
obtain
pcr
detect
respiratori
virus
biofir
diagnost
formerli
idaho
technolog
salt
lake
citi
ut
durat
present
studi
techniqu
yet
approv
detect
mycoplasma
chlamydophila
urin
studi
legionella
pneumococcu
antigen
binaxnow
aler
san
diego
ca
serum
procalcitonin
assay
vida
biomerieux
durham
nc
port
score
port
sever
index
calcul
procalcitonin
level
interpret
follow
valu
mgml
strongli
oppos
presenc
bacteri
infect
oppos
bacteri
infect
suggest
bacteri
infect
strongli
favor
bacteri
infect
clinic
laboratori
radiolog
data
collect
onto
spread
sheet
viral
pcr
result
procalcitonin
level
initi
mask
regular
interv
two
three
investig
alway
includ
senior
investig
review
tabul
data
togeth
electron
medic
record
agre
initi
clinic
diagnosi
result
viral
studi
unmask
case
review
reach
final
clinic
diagnosi
procalcitonin
level
unmask
order
determin
congruenc
final
clinic
diagnosi
definit
final
diagnos
design
refin
stage
origin
definit
design
studi
began
patient
enrol
data
analyz
definit
refin
data
accru
minim
diagnost
refin
end
accrual
period
case
rereview
light
final
set
definit
patient
assign
final
clinic
diagnos
base
follow
criteria
patient
welldocu
caus
infect
present
find
togeth
support
laboratori
data
eg
elev
bnatriuret
protein
document
lung
mass
x
ray
none
criteria
bacteri
viral
infect
describ
proven
like
bacteri
pathogen
isol
normal
steril
bodi
site
urin
assay
pneumococcu
legionella
antigen
posit
presumpt
like
bacteri
pathogen
observ
microscop
predomin
organ
goodqual
sputum
specimen
cultur
document
presenc
organ
pcr
identifi
influenza
parainfluenza
respiratori
syncyti
human
metapneumo
corona
rhinoor
adenoviru
pneumocysti
jiroveci
detect
bronchial
secret
strong
clinic
diagnosi
appropri
host
respons
direct
antimicrobi
therapi
bacteri
fungal
infect
togeth
posit
viral
pcr
infect
unknown
caus
patient
thought
infect
microbiolog
caus
identifi
stratifi
follow
like
bacteri
follow
absenc
upper
respiratori
symptom
presenc
biphas
respiratori
ill
acut
deterior
hyperacut
present
present
sepsi
shock
wbc
count
increas
band
form
dens
segment
lobar
consolid
like
nonbacteri
follow
exposur
sick
contact
upper
respiratori
symptom
patchi
infiltr
plu
absenc
find
suggest
like
bacteri
caus
undetermin
failur
fit
either
categori
dichotom
data
presenc
absenc
find
compar
among
group
chi
squar
test
small
group
fisher
exact
use
continu
variabl
normal
distribut
student
test
use
result
normal
distribut
anova
use
signific
set
p
valu
year
observ
hospit
patient
syndrom
met
criteria
cap
agre
particip
studi
demograph
common
comorbid
condit
list
tabl
patient
receiv
antibiot
treatment
admiss
treatment
follow
accept
guidelin
case
blood
cultur
admiss
case
urin
assay
pneumococc
legionella
antigen
case
respect
sputum
sampl
gram
stain
cultur
obtain
case
judg
inadequ
obtain
h
antibiot
begun
thu
adequ
sputum
sampl
obtain
within
h
antibiot
administr
case
viral
pcr
nasopharyng
swab
done
case
serum
procalcitonin
admiss
assay
everi
patient
patient
stratifi
one
follow
final
diagnost
classif
follow
tabl
fortyfour
patient
uninfect
congest
heart
failurefluid
overload
lung
cancer
compar
patient
cap
tabl
less
like
fever
p
like
heart
diseas
p
consist
preval
pulmonari
edema
mean
wbc
count
significantli
lower
patient
bacteri
pneumonia
p
differ
patient
tabl
number
patient
proven
infect
shown
parenthes
proport
cough
sputum
product
short
breath
pleurit
chest
pain
confus
pneumonia
frequent
implic
bacteri
caus
case
repres
case
cap
twelv
patient
haemophilu
influenza
sputum
six
togeth
pneumococcu
bacterem
pneumococc
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
next
frequent
bacteri
isol
coinfect
viru
identifi
pcr
patient
bacteri
pneumonia
e
rhinoviru
case
respiratori
syncyti
viru
rsv
mean
wbc
count
patient
bacteri
pneumonia
ae
differ
proven
presumpt
infect
p
z
tabl
eight
patient
suppress
wbc
respons
wbc
normal
wbc
count
mean
procalcitonin
ae
valu
higher
patient
proven
presumpt
bacteri
infect
p
z
case
bacteri
infect
proven
presumpt
procalcitonin
case
proven
presumpt
procalcitonin
patient
bacteri
infect
procalcitonin
port
risk
group
port
score
index
psi
procalcitonin
although
none
psi
result
indic
low
procalcitonin
level
time
admiss
reli
upon
exclud
likelihood
seriou
bacteri
infect
infect
viral
pcr
identifi
total
respiratori
virus
patient
cap
e
pathogen
detect
togeth
bacteri
fungal
pathogen
patient
influenza
viru
infect
consist
high
uptak
influenza
vaccin
popul
absenc
major
influenza
outbreak
year
studi
fever
cough
sputum
product
myalgia
chest
pain
confus
hypoxia
present
proport
similar
patient
bacteri
pneumonia
tabl
mean
wbc
count
mean
procalcitonin
significantli
lower
patient
bacteri
infect
p
p
respect
nevertheless
procalcitonin
patient
patient
viral
infect
show
elev
level
exclud
diagnosi
viral
pneumonia
three
patient
clinic
characterist
suggest
bacteri
pneumonia
biphas
ill
wbc
count
dens
infiltr
bacterium
recov
three
remov
averag
wbc
count
patient
viral
pneumonia
averag
procalcitonin
six
patient
untreat
inadequ
treat
hiv
infect
p
jiroveci
pneumonia
one
coinfect
rhinoviru
subject
mean
wbc
count
mean
procalcitonin
one
hundr
nineteen
patient
thought
infecti
caus
cap
syndrom
larg
exclus
noninfecti
caus
etiolog
agent
identifi
use
definit
state
method
patient
stratifi
follow
like
bacteri
judg
like
bacteri
infect
accord
criteria
specifi
method
section
patient
mean
wbc
mean
procalcitonin
procalcitonin
prospect
observ
studi
systemat
appli
current
avail
fdaapprov
diagnost
techniqu
studi
patient
hospit
cap
tertiari
care
veteran
hospit
period
fortyfour
patient
judg
infect
although
diagnos
cap
treat
antibiot
thought
infect
bacteri
caus
identifi
viral
caus
document
bacteri
coinfect
p
jiroveci
infect
thu
major
patient
thought
infect
etiolog
diagnosi
ever
determin
clinic
syndrom
laboratori
find
suggest
bacteri
infect
viral
infect
indetermin
remain
pneumococcu
caus
case
bacteri
infecti
etiolog
establish
repres
infect
patient
remark
differ
found
preantibiot
era
studi
found
pneumonia
cap
european
studi
highest
report
yield
pneumococcu
util
nontradit
techniqu
fulli
valid
use
lung
punctur
ruizgonzalez
et
al
attribut
cap
pneumococcu
quantit
pcr
nasal
wash
detect
pneumonia
african
aid
patient
pneumonia
still
substanti
lower
percentag
might
expect
patient
popul
one
possibl
explan
low
rate
diagnosi
pneumococc
pneumonia
failur
detect
organ
infect
patient
provid
adequ
sputum
sampl
within
h
initi
antibiot
yield
pneumococci
fall
greatli
time
routin
use
nebul
induc
sputum
emerg
depart
might
increas
yield
preliminari
studi
unpublish
found
use
dna
hybrid
accuprob
genprob
san
diego
ca
whole
sputum
sputum
cultur
plate
may
identifi
pneumococci
small
proport
case
contrast
pneumococc
antigen
detect
system
binax
use
high
proport
fals
posit
c
stager
musher
unpublish
observ
result
howev
support
low
frequenc
pneumococc
infect
cap
blood
cultur
urin
test
pneumococc
antigen
posit
conserv
estim
case
pneumococc
pneumonia
bacterem
test
detect
cell
wall
polysaccharid
posit
bacterem
case
nonbacterem
case
pneumococc
infect
would
still
exceed
infect
patient
use
multiplex
pcr
pneumococc
capsular
polysaccharid
urin
might
slightli
increas
yield
secular
trend
may
led
reduct
preval
pneumonia
caus
pneumonia
widespread
use
pneumococc
polysaccharid
vaccin
popul
elig
patient
serv
medvamc
vaccin
conjug
vaccin
children
houston
uptak
infant
toddler
certainli
reduc
frequenc
pneumococc
diseas
adult
direct
indirect
effect
pneumococc
coloni
may
difficult
detect
blood
agar
plate
preval
alphahemolyt
streptococci
contrast
laboratori
identif
potenti
pulmonari
pathogen
e
eg
aureu
h
influenza
gram
neg
bacilli
e
rel
easi
pneumococci
respons
mani
case
cap
bacteria
identifi
unclear
organ
respons
one
wonder
whether
could
mix
respiratori
flora
swedish
infecti
diseas
societi
recommend
penicillin
treatment
cap
observ
respons
would
consist
either
undetect
pneumococcu
mix
respiratori
flora
caus
agent
pcr
identifi
respiratori
viru
infect
patient
slightli
lower
proport
report
seri
one
consist
age
patient
much
higher
proport
healthi
adult
two
reason
identifi
viru
patient
pneumonia
prove
causal
relationship
asymptomat
adult
may
carri
one
virus
viral
respiratori
ill
may
predispos
secondari
bacteri
infect
exclus
patient
document
bacteri
coinfect
significantli
lower
mean
wbc
count
procalcitonin
level
patient
viral
pcrposit
support
diagnosi
viral
pneumonia
mean
pct
greater
patient
document
viral
infect
unknown
like
viral
group
patient
latter
group
identifi
clinic
would
exclud
featur
consist
bacteri
pneumonia
contrast
patient
confirm
viral
infect
select
restrict
may
also
bacteri
infect
proven
mean
psi
score
nearli
ident
coinfect
patient
bacteri
infect
p
z
oppos
recent
suggest
coinfect
patient
sever
ill
bacteri
infect
alon
major
strength
studi
includ
patient
syndrom
consist
cap
exclud
patient
subsequ
judg
uninfect
patient
admit
cap
uninfect
congest
heart
failur
pulmonari
edema
may
difficult
distinguish
pneumonia
symptom
sign
includ
wbc
count
overlap
pneumonia
symptom
older
person
nonspecif
fever
may
present
pneumonia
onehalf
patient
pneumonia
temperatur
f
first
h
hospit
unmask
procalcitonin
level
found
much
lower
uninfect
patient
bacteri
pneumonia
find
might
reinforc
willing
withhold
antibiot
case
despit
intens
effort
identifi
etiolog
agent
none
found
cap
patient
seri
appli
clinic
criteria
develop
review
first
patient
seri
determin
clinic
laboratori
find
strongli
suggest
bacteri
infect
eighteen
clinic
syndrom
close
resembl
viral
pneumonia
result
procalcitonin
assay
support
valid
clinic
criteria
infer
could
made
regard
remain
case
consist
earlier
report
found
clear
differ
mean
serum
procalcitonin
level
patient
bacteri
infect
uninfect
viral
fungal
infect
howev
nearli
onethird
patient
document
bacteri
infect
procalcitonin
level
gener
associ
bacteri
infect
onethird
without
bacteri
infect
level
associ
bacteri
infect
lack
specif
preclud
depend
test
select
initi
treatment
care
attent
clinic
laboratori
find
suggest
bacteri
infect
present
low
procalcitonin
level
might
support
withhold
antibiot
recent
metaanalysi
suggest
monitor
procalcitonin
level
may
allow
durat
antibiot
treatment
reduc
day
without
advers
affect
outcom
howev
care
attent
clinic
detail
might
studi
support
concern
hospit
cap
like
lead
unnecessari
antibiot
therapi
addit
patient
uninfect
viral
pneumonia
infect
mycobacterium
nocardia
pneumocysti
syndrom
regard
suggest
viral
infect
although
viral
pcr
neg
thu
patient
admit
diagnosi
cap
treat
empir
antibiot
littl
chanc
benefit
find
stimul
thought
applic
guidelin
empir
therapi
provid
impetu
develop
better
diagnost
studi
princip
limit
research
carri
singl
medic
center
male
middleag
popul
predomin
enrol
singl
medic
center
howev
offer
potenti
advantag
consist
data
although
also
possibl
consist
bia
data
collect
analysi
studi
also
limit
pcr
technolog
use
yet
fdaapprov
detect
mycoplasma
chlamydia
chose
attempt
diagnos
infect
serolog
conclus
mani
problem
remain
diagnos
treat
cap
seri
case
patient
admit
diagnosi
even
infect
care
clinic
analysi
better
antibiot
stewardship
would
led
correct
diagnosi
admiss
anoth
viral
infect
onequart
secondari
bacteri
infect
although
current
pcr
technolog
rel
simpl
detect
viral
infect
much
difficult
exclud
presenc
secondari
bacteri
infect
patient
fungal
mycobacteri
nocardi
infect
also
initi
diagnos
cap
although
mani
good
evid
time
admiss
bacteri
infect
respons
import
larg
group
patient
e
seri
e
diagnosi
could
made
patient
receiv
standard
antibacteri
therapi
admiss
induc
sputum
emerg
depart
might
lead
correct
diagnosi
proport
case
addit
techniqu
might
help
identifi
pneumococci
sputum
routin
use
assay
serum
procalcitonin
level
may
help
diagnosi
especi
indic
patient
bacteri
infect
data
show
clearli
facil
use
guidelin
label
patient
cap
treat
antibiot
problemat
better
discrimin
bacteri
infect
sore
need
